Decision slated for early September.
The US FDA will decide whether to approve Biocon and Mylan’s version of the Roche breast cancer drug Herceptin by the beginning of September, as reported by BioPharm Reporter.
Indian drugmakers Biocon and Mylan, which are developing six biosimilar monoclonal antibodies for global markets, announced today their first US submission has been accepted for review by the US Food and Drug Administration (FDA).
The biologics license application (BLA) for the proposed biosimilar version of Roche/Genetech’s Herceptin (trastuzumab) was filed through the 351(k) pathway and the Agency has given the date of September 3, 2017 as its decision date as to whether or not it is to be approved.
MYL-1401O was submitted to the Agency in November, and if approved the two companies say it will be the first biosimilar to challenge Herceptin in the US.
“We believe that our comprehensive package of analytical similarity, non-clinical and clinical data submitted with the BLA will demonstrate similarity of the proposed biosimilar trastuzumab to the reference product,” Mylan’s president Rajiv Malik said in a statement.
Biocon CEO Arun Chandavarkar added: “This development positions Biocon and Mylan among the first companies to be able to address the critical need of U.S. patients for a high-quality biosimilar to treat certain HER2-positive breast cancers, in the near future.”
The biosimilar trastuzumab is also under review by the European Medicines Agency (EMA).
Source: BioPharm Reporter
Part 1: Unlocking the Potential of Biosimilars to Improve Health Equity
May 7th 2024Biosimilars offer a promising path to affordable, effective treatment, but barriers remain for underserved communities. This 2-part series explores the potential of biosimilars to improve health equity while addressing the obstacles that currently prevent access.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.